Molecular Docking Studies to Identify Anti-Cancerous Potentials to Prevent Breast Cancer

Main Article Content

Kathirvel Kalaiselvi

Abstract

 Estrogen exerts many of its effects via two nuclear estrogen receptors (ERs), ERα and ERβ.  The overall structure of ERbeta-LBD is very similar to that previously reported for ERalpha. The discovery of a second ER, ERβ, demanded a full re-evaluation of estrogen action in all target tissues and different estrogen associated diseases, including human breast cancer. Expression of ERβ in breast cancer has been analyzed at the mRNA or protein level in several clinical materials. However, despite their being defined by the absence of ER-α expression, 55% of HER2-type and 60% of basal-like cancers showed expression of ER-β.  The role of ER-β in the development and progression of breast cancers defined by lack of expression of ER-α merits further investigation. Estrogen receptor beta as a novel target of androgen receptor action in breast cancer cell lines. Our finding has the potential to extend further toward drug development against ERbeta In this current study it is taken as attractive drug target protein for docking study.

Article Details

Section
Articles